Lukas Lochman

Lukas Lochman

Auto-generated profile, based on publicly available information

Lukas Lochman

Department of Pharmaceutical Chemistry and Pharmaceutical Analysis, Faculty of Pharmacy in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

16 May 2019 in ACS Sensors
Verified
Journal Article
Closed access
LLLukas Lochman
Lukas Lochman
MMMiloslav Machacek
Miloslav Machacek
MMMiroslav Miletin
Miroslav Miletin
ŠUŠtěpánka Uhlířová
Štěpánka Uhlířová
KLKamil Lang
Kamil Lang
VNVeronika Novakova
Veronika Novakova

1 July 2017 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
LLLukas Lochman
Lukas Lochman
PZPetr Zimčík
Petr Zimčík
IKIngo Klimant
Ingo Klimant
VNVeronika Novakova
Veronika Novakova
SBSergey M. Borisov
Sergey M. Borisov

19 March 2013 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
VNVeronika Novakova
Veronika Novakova
LLLukáš Lochman
Lukáš Lochman
IZIvana Zajícová
Ivana Zajícová
KKKamil Kopecky
Kamil Kopecky
MMMiroslav Miletin
Miroslav Miletin
PZPetr Zimčík
Petr Zimčík

8 January 2016 in Chemistry – A European Journal
Verified
Journal Article
Closed access
PDF file
LLLukas Lochman
Lukas Lochman
JSJan Svec
Jan Svec
JRJaroslav Roh
Jaroslav Roh
KKKaplan Kirakci
Kaplan Kirakci
KLKamil Lang
Kamil Lang
VNVeronika Novakova
Veronika Novakova

15 April 2025 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
LLLukáš Lochman
Lukáš Lochman
EKEllen Tanaka Kahiya
Ellen Tanaka Kahiya
BSBechara Saade
Bechara Saade
TSTomáš Smutný
Tomáš Smutný
JTJurjen Duintjer Tebbens
Jurjen Duintjer Tebbens
VBVeronika Bernhauerová
Veronika Bernhauerová
Xenoreceptors of the nuclear receptor superfamily, such as pregnane X receptor (PXR), are liver-enriched ligand-activated transcription factors regarded as crucial sensors in xenobiotic exposure and detoxification. PXR controls transcription of many drug-handling genes and influx/efflux transporters, thus playing a crucial role in drug metabolism and excretion. Liver functions have been studied using primary human hepatocytes (PHHs), which, when conventionally cultured, undergo rapid de-differentiation, leaving them unsuitable for long-term studies. Recently, 3D PHHs called spheroids have emerged as an in vitro model that is similar to in vivo hepatocytes regarding phenotype and function and represents the first in vitro model to study the long-term regulation of drug-handling genes by PXR. In this study, we used mathematical modelling to analyze the long-term activation of PXR in 3D PHHs through expression kinetics of three key PXR-regulated drug-metabolizing enzymes, CYP3A4, CYP2C9, and CYP2B6 and the P-glycoprotein efflux transporter encoding gene, MDR1. PXR action in 3D PHHs was induced by the antibiotic rifampicin at two clinically relevant concentrations. The results confirmed that high rifampicin concentrations activated PXR nearly to its full capacity. The analysis indicated the highest PXR-induced transcription rate constant for CYP2B6. The rate constant dictating mRNA degradation associated with activated PXR was highest for CYP3A4. Moreover, we measured the metabolic activity of CYP3A4, CYP2C9, and CYP2B6 and quantified their metabolic rate constants. Metabolic activity rate constant of CYP3A4 was found to be the highest whereas that of CYP2B6 was found to be the lowest among the studied enzymes. Our results provide important insight into the regulation of PXR-target genes in 3D PHHs and show that mRNA expression and metabolic activity data can be combined with quantitative analysis to reveal the long-term action of PXR and its effects on drug-handling genes.